Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reply to ‘Proteasome inhibition therapies in childhood cancer’ by Zaman et al.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Zaman F, Fadeel B, Savendahl L . Proteasome inhibition therapies in childhood cancer. Leukemia 2008; 22: 883–884.

    Article  CAS  PubMed  Google Scholar 

  2. Terpos E, Dimopoulos MA, Sezer O . The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875–1884.

    Article  CAS  PubMed  Google Scholar 

  3. Zaman F, Menendez-Benito V, Eriksson E, Chagin AS, Takigawa M, Fadeel B et al. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Cancer Res 2007; 67: 10078–10086.

    Article  CAS  PubMed  Google Scholar 

  4. Terpos E, Sezer O, Croucher PI, Dimopoulos MA . Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110: 1098–1104.

    Article  CAS  PubMed  Google Scholar 

  5. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025–2034.

    Article  CAS  PubMed  Google Scholar 

  6. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappa B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688–692.

    Article  CAS  PubMed  Google Scholar 

  7. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T . The ubiquitin–proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773–785.

    Article  CAS  Google Scholar 

  8. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334–338 .

    Article  CAS  PubMed  Google Scholar 

  9. Wu S, De Luca F . Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth. Endocrinology 2006; 147: 3761–3768.

    Article  CAS  PubMed  Google Scholar 

  10. Alexander DD, Mink PJ, Adami HO, Cole P, Man del JS, Oken MM et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007; 120 (Suppl 12): 40–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E Terpos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terpos, E., Sezer, O. Reply to ‘Proteasome inhibition therapies in childhood cancer’ by Zaman et al.. Leukemia 22, 884–885 (2008). https://doi.org/10.1038/sj.leu.2404998

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404998

Search

Quick links